Showing 1 – 5 of 5
Relevance | Newest | Oldest |
  • Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy

    Abstract Full Text
    online first
    JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0578

    This cohort study examines oncological outcomes after sentinel lymph node biopsy with dual-tracer mapping or targeted axillary dissection.

  • Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era

    Abstract Full Text
    JAMA Surg. 2023; 159(2):193-201. 10.1001/jamasurg.2023.6382

    This cohort study estimates the risk of breast cancer among women diagnosed with histopathologic benign breast disease in the era of percutaneous biopsy vs historical surgical biopsy.

  • Association of Low Nodal Positivity Rate Among Patients With ERBB2 -Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy

    Abstract Full Text
    free access
    JAMA Surg. 2018; 153(12):1120-1126. 10.1001/jamasurg.2018.2696

    This study of the National Cancer Database evaluated the association of nodal positivity rates with a pathologic complete response to neoadjuvant chemotherapy among patients with cT1/cT2 cN0 triple-negative breast cancer or ERBB2-positive disease.

  • Need for a Revised Staging Consensus in Medullary Thyroid Carcinoma

    Abstract Full Text
    free access
    Arch Surg. 2009; 144(7):663-669. 10.1001/archsurg.2009.122
  • Temporal Trends in Infective Endocarditis: A Population-Based Study in Olmsted County, Minnesota

    Abstract Full Text
    free access
    JAMA. 2005; 293(24):3022-3028. 10.1001/jama.293.24.3022